Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Increase in Short Interest

Coherus BioSciences, Inc. (NASDAQ:CHRS) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 19,840,000 shares, a growth of 6.0% from the October 15th total of 18,720,000 shares. Based on an average trading volume of 3,710,000 shares, the days-to-cover ratio is presently 5.3 days.

Coherus BioSciences Stock Performance

Coherus BioSciences stock opened at $2.13 on Friday. The stock has a market cap of $237.20 million, a PE ratio of -0.81 and a beta of 0.87. Coherus BioSciences has a one year low of $1.43 and a one year high of $10.99. The stock has a fifty day moving average of $3.45 and a 200 day moving average of $4.32.

Institutional Trading of Coherus BioSciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Captrust Financial Advisors increased its position in Coherus BioSciences by 1,461.0% in the first quarter. Captrust Financial Advisors now owns 2,404 shares of the biotechnology company’s stock worth $31,000 after buying an additional 2,250 shares in the last quarter. Eagle Bay Advisors LLC increased its position in Coherus BioSciences by 136.1% in the second quarter. Eagle Bay Advisors LLC now owns 3,891 shares of the biotechnology company’s stock worth $28,000 after buying an additional 2,243 shares in the last quarter. Federated Hermes Inc. increased its position in Coherus BioSciences by 55.0% in the third quarter. Federated Hermes Inc. now owns 4,223 shares of the biotechnology company’s stock worth $41,000 after buying an additional 1,498 shares in the last quarter. Dark Forest Capital Management LP purchased a new stake in Coherus BioSciences in the first quarter worth about $66,000. Finally, Dorsey & Whitney Trust CO LLC purchased a new stake in Coherus BioSciences in the third quarter worth about $39,000. Hedge funds and other institutional investors own 91.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Bank of America dropped their target price on Coherus BioSciences from $7.00 to $6.00 in a report on Thursday, October 12th. StockNews.com initiated coverage on Coherus BioSciences in a report on Thursday, October 5th. They set a “hold” rating on the stock. HC Wainwright lowered their price target on Coherus BioSciences from $20.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Barclays lowered their price target on Coherus BioSciences from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday, October 23rd. Finally, Maxim Group downgraded Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.78.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States.